Compare Hims and Hers Health Inc (HIMS) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Verisign, Inc. — how do they compare? Hims and Hers Health Inc trades at $29.35 (market cap $6.55B), while Verisign, Inc. trades at $305.53 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 4.1× Hims and Hers Health Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Verisign, Inc. for 123 Days on average.
| HIMS | VRSN | |
|---|---|---|
Market Cap | $6.55B | $26.92B |
Volume | 14,842,814 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $62.76 | $310.00 |
52-Week Low | $14.52 | $211.49 |
Typical Hold Time | 21 Days | 123 Days |
Enterprise Value | $7.25B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
VeriSign (VRSN) trades at $305.53, up 3.84% today, with a bullish technical outlook and strong institutional buying. The company reported solid Q2 2026 results with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations slightly. High profitability is evident with a net income margin near 50%, but valuation multiples like P/E of 32.33 are elevated. Recent news includes an antitrust lawsuit and insider selling by the CEO, while major institutions like BlackRock have increased stakes.
The stock offers growth potential from domain registration increases and AI-driven demand, with a consensus price target of $348 implying 14% upside. Risks include regulatory scrutiny from the antitrust case, high debt levels, and premium valuation. Analyst sentiment is positive with 60% buy ratings, but investors should monitor Q3 2026 earnings on October 22 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
